PHASE I HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PERIPHERAL VASCULAR DISEASE

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 最近的研究表明，骨髓和血液造血干细胞可能有助于多器官系统中的非造血组织修复。 在动物模型中，以及最近在有限的人体试验中，已报道未纯化的骨髓单核细胞和/或成人造血干细胞亚群有助于新血管生成。 由于造血干细胞（HSC）的亚群均为CD 34+和AC 133+，并且AC 133+细胞被认为是更原始的内皮细胞前体，因此本试验将使用Miltenyi CliniMACS细胞分离器分离的自体AC 133+造血干细胞经皮移植至患有难治性和非手术性下肢外周血管疾病的患者体内。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent studies have suggested that marrow and blood hematopoietic stem cells may contribute to non-hematopoietic tissue repair in multiple organ systems. In animal models, and more recently in limited human trials, unpurified marrow mononuclear cells and /or subsets of adult hematopoietic stem cells have been reported to contribute to neo-angiogenesis. Since the subset of hematopoietic stem cells (HSC) are both CD34+ and AC133+, and since AC133+ cells are considered more primitive and endothelial cell precursors, this trial will utilize autologous AC133+ hematopoietic stem cells isolated with the Miltenyi CliniMACS cell separator for percutaneous transplant into patients with medically refractory and non-surgical peripheral vascular disease of the lower extremity.